Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription
- PMID: 29948107
- DOI: 10.1007/s00259-018-4064-6
Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription
Abstract
Purpose: The aim of this study was to establish an algorithm for the prescription of 90Y glass microsphere radioembolization (90Y-GMRE) of HCC in individual patients based on the relationship between tumour dose (TD) and response validated by 90Y PET/CT dosimetry and dual-tracer PET/CT metabolic parameters.
Methods: The study group comprised 62 HCC patients prospectively recruited for 90Y-GMRE who underwent pretreatment dual-tracer (11C-acetate and 18F-FDG) PET/CT as surrogate markers of HCC cellular differentiation. Pretreatment tumour-to-nontumour ratio on 99mTc-MAA SPECT/CT (T/NTMAA) was correlated with posttreatment 90Y PET/CT T/NT90Y after quantification validation. The TD-response relationship for HCC of different tracer groups was assessed on follow-up PET/CT 2 months after treatment.
Results: 90Y PET/CT was accurate in the measurement of recovery of injected 90Y activity (81.9-99.9%, median 94.8%). Pretreatment SPECT/CT T/NTMAA was strongly correlated with posttreatment 90Y PET/CT T/NT90Y (5.6 ± 3.2 versus 5.9 ± 3.5, T/NT90Y 1.01 × T/NTMAA + 0.161, r = 0.918, P < 0.05). The response rates were 72.4% (21/29), 70.6% (12/17) and 25% (4/16) for well, moderately and poorly differentiated HCC, respectively. The cut-off TD for a good response was significantly different between poorly differentiated and well/moderately differentiated HCC (262 Gy versus 152/174 Gy) with 89.2% sensitivity and 88% specificity. At a limiting tolerated liver dose of 70 Gy, the T/NTMAA thresholds for predicting a good response in poorly differentiated and well/moderately differentiated HCC were 3.5 and 2.0/2.3. Disregarding HCC cellular differentiation, the cut-off TD became 170 Gy, with lower sensitivity (70.3%) and specificity (76%).
Conclusion: 90Y PET/CT can provide accurate dosimetry for 90Y-GMRE. Pretreatment T/NTMAA predicts posttreatment T/NT90Y. The TD thresholds for a good response are tracer-dependent, with a strong correlation between HCC radiosensitivity and cellular differentiation and other PET-based parameters. These cytokinetic factors improve treatment efficacy while minimizing organ damage for the prescription of personalized 90Y-GMRE.
Keywords: 90Y glass microspheres; Dosimetry; HCC; PET/CT; Radioembolization; Tumour grade.
Comment in
-
90Y-radioembolization of hepatocellular carcinoma from a theranostic perspective: towards a personalized approach.Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2238-2239. doi: 10.1007/s00259-018-4115-z. Epub 2018 Aug 7. Eur J Nucl Med Mol Imaging. 2018. PMID: 30083825 No abstract available.
Similar articles
-
Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.J Nucl Med. 2016 Nov;57(11):1672-1678. doi: 10.2967/jnumed.116.173104. Epub 2016 Jun 15. J Nucl Med. 2016. PMID: 27307346
-
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.J Nucl Med. 2012 Feb;53(2):255-63. doi: 10.2967/jnumed.111.094235. J Nucl Med. 2012. PMID: 22302962
-
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.J Nucl Med. 2015 Mar;56(3):339-46. doi: 10.2967/jnumed.114.145177. Epub 2015 Feb 12. J Nucl Med. 2015. PMID: 25678490
-
Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma.PET Clin. 2019 Oct;14(4):459-467. doi: 10.1016/j.cpet.2019.06.005. Epub 2019 Jul 31. PET Clin. 2019. PMID: 31472743 Review.
-
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):559-75. doi: 10.1007/s00259-015-3157-8. Epub 2015 Sep 4. Eur J Nucl Med Mol Imaging. 2016. PMID: 26338177 Free PMC article. Review.
Cited by
-
The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure.Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):816-827. doi: 10.1007/s00259-019-04588-x. Epub 2019 Nov 18. Eur J Nucl Med Mol Imaging. 2020. PMID: 31741021
-
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1682-1699. doi: 10.1007/s00259-021-05600-z. Epub 2022 Feb 11. Eur J Nucl Med Mol Imaging. 2022. PMID: 35146577 Free PMC article.
-
Yttrium-90 TOF-PET-Based EUD Predicts Response Post Liver Radioembolizations Using Recommended Manufacturer FDG Reconstruction Parameters.Front Oncol. 2021 Oct 5;11:592529. doi: 10.3389/fonc.2021.592529. eCollection 2021. Front Oncol. 2021. PMID: 34676157 Free PMC article.
-
Activation of nano-photosensitizers by Y-90 microspheres to enhance oxidative stress and cell death in hepatocellular carcinoma.Sci Rep. 2022 Jul 26;12(1):12748. doi: 10.1038/s41598-022-17185-0. Sci Rep. 2022. PMID: 35882949 Free PMC article.
-
Beyond the MAA-Y90 Paradigm: The Evolution of Radioembolization Dosimetry Approaches and Scout Particles.Semin Intervent Radiol. 2021 Nov 24;38(5):542-553. doi: 10.1055/s-0041-1736660. eCollection 2021 Dec. Semin Intervent Radiol. 2021. PMID: 34853500 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials